Smit, Egbert F.
Garon, Edward B.
Reck, Martin
Cappuzzo, Federico
Bidoli, Paolo
Cohen, Roger B.
Gao, Ling
O’Brien, Lisa M.
Lee, Pablo
Zimmermann, Annamaria
Ferry, David R.
Melemed, Allen S.
Pérol, Maurice
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 1 September 2017
Accepted: 3 March 2018
First Online: 2 May 2018
Compliance with ethical standards
:
: Ling Gao, Lisa M. O’Brien, Pablo Lee, Annamaria Zimmermann, David R. Ferry, and Allen S. Melemed are full-time employees and stockholders of Eli Lilly and Company. Egbert F. Smit has received honoraria from Eli Lilly and Company. Edward B. Garon received research funding from AstraZeneca, Bristol-Myers Squibb, Genentech, Merck, Mirati, Pfizer, Novartis, Boehringer Ingelheim, and Eli Lilly and Company. Martin Reck has received honoraria for lectures and consultancy from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Merck, Merck Sharp & Dohme, Novartis, Pfizer, and Roche/Genentech. Federico Cappuzzo has received consultancy fees from Eli Lilly and Company. Maurice Pérol has received honoraria as a consultant/advisory board member for Eli Lilly and Company. Paolo Bidoli is on the advisory board for Boehringer Ingelheim, Bristol-Myers Squibb, and Eli Lilly and Company. Roger B. Cohen declares grant support to his institution from ImClone. This study is funded by Eli Lilly and Company.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.